TargetMol

Mirodenafil dihydrochloride

Product Code:
 
TAR-TQ0126
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-TQ0126-5mg5mg£118.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-TQ0126-1mL1 mL * 10 mM (in DMSO)£135.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-TQ0126-10mg10mg£142.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-TQ0126-25mg25mg£193.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-TQ0126-50mg50mg£269.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-TQ0126-100mg100mg£409.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-TQ0126-500mg500mg£839.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
Mirodenafil dihydrochloride is a PDE-5 inhibitor developed for the treatment of erectile dysfunction.
CAS:
862189-96-6
Formula:
C26H39Cl2N5O5S
Molecular Weight:
604.59
Pathway:
Metabolism
Purity:
0.9946
SMILES:
Cl.Cl.CCCOc1ccc(cc1-c1nc2c(CCC)cn(CC)c2c(=O)[nH]1)S(=O)(=O)N1CCN(CCO)CC1
Target:
PDE

References

Kim, B.H., et al., Influence of alcohol on the hemodynamic effects and pharmacokinetic properties of mirodenafil: a single-dose, randomized-sequence, open-label, crossover study in healthy male volunteers in Korea. Clin Ther, 2009. 31(6): p. 1234-43. Paick, J.S., et al., Efficacy and safety of mirodenafil, a new oral phosphodiesterase type 5 inhibitor, for treatment of erectile dysfunction. J Sex Med, 2008. 5(11): p. 2672-80.